Prognostic Factors for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer Receiving Neoadjuvant FOLFIRINOX

BACKGROUND/AIMS: There has been growing evidence on the utility of neoadjuvant FOLFIRINOX in borderline resectable (BR) or locally advanced (LA) pancreatic cancer. However, factors predicting survival in these patients remain to be identified, and we aimed to identify these prognostic factors. METHO...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Gut Liver
Autors principals: Choi, Young Hoon, Lee, Sang Hyub, You, Min Su, Shin, Bang Sup, Paik, Woo Hyun, Ryu, Ji Kon, Kim, Yong-Tae, Kwon, Wooil, Jang, Jin-Young, Kim, Sun-Whe
Format: Artigo
Idioma:Inglês
Publicat: Editorial Office of Gut and Liver 2021
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7960979/
https://ncbi.nlm.nih.gov/pubmed/32235008
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5009/gnl19182
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars